These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 27382454

  • 1. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine.
    Hassan MA, Tolba OA.
    Electron Physician; 2016 May; 8(5):2425-31. PubMed ID: 27382454
    [Abstract] [Full Text] [Related]

  • 2. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [Abstract] [Full Text] [Related]

  • 4. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 5. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.
    Aydinok Y, Unal S, Oymak Y, Vergin C, Türker ZD, Yildiz D, Yesilipek A.
    Eur J Haematol; 2012 May; 88(5):431-8. PubMed ID: 22335829
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 7. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 8. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K, Sivaramakrishnan G.
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
    Dou H, Qin Y, Chen G, Zhao Y.
    Acta Haematol; 2019 Jun; 141(1):32-42. PubMed ID: 30504715
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA, Hamam MA, Taha OA, Hazaa SM.
    Infect Disord Drug Targets; 2015 Jun; 15(2):98-105. PubMed ID: 26205801
    [Abstract] [Full Text] [Related]

  • 12. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
    Takpradit C, Viprakasit V, Narkbunnam N, Vathana N, Phuakpet K, Pongtanakul B, Sanpakit K, Buaboonnam J.
    Pediatr Int; 2021 Apr; 63(4):404-409. PubMed ID: 32856363
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Apr; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 15. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS, Saber MM, Adly AA, Ismail EA, Tarif M, Ibrahim F, Elalfy OM.
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [Abstract] [Full Text] [Related]

  • 16. Use of Iron Chelating Agents in Transfusion Dependent Thalassaemia Major Patients.
    Santra S, Bhattacharya A, Mukhopadhyay T, Agrawal D, Kumar S, Das P, Chakrabarty P.
    Mymensingh Med J; 2015 Oct; 24(4):838-44. PubMed ID: 26620028
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R, Ahmed J, Krishnan P, Jankharia B.
    Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
    [Abstract] [Full Text] [Related]

  • 18. Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients.
    Bordbar M, Haghpanah S, Zekavat OR, Saki F, Bazrafshan A, Bozorgi H.
    Expert Rev Hematol; 2019 Nov; 12(11):997-1003. PubMed ID: 31486684
    [Abstract] [Full Text] [Related]

  • 19. Cost-Utility Analysis of four Chelation Regimens for β-thalassemia Major: a Chinese Perspective.
    Li J, Wang P, Li X, Wang Q, Zhang J, Lin Y.
    Mediterr J Hematol Infect Dis; 2020 Nov; 12(1):e2020029. PubMed ID: 32395218
    [Abstract] [Full Text] [Related]

  • 20. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Nov; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.